Evidence map›Paper›PMID 34437922›Full record

ReviewThe Journal of allergy and clinical immunology2021

JAK inhibitors in the treatment of atopic dermatitis.

Raj Chovatiya, Amy S Paller

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of allergy and clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06361992 (Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children), which is not on this map. Cited by 184 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 10 pooled it
44.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06361992 phase3completednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children

TypeinterventionalSponsorCatalysis SLRan2022 to 2024Enrolled58ConditionsAtopic Dermatitis, Atopic Dermatitis and Related Conditions, Atopic Dermatitis Eczema, Atopic Dermatitis \(AD\)ArmsBlue Cap Foam
3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 10 syntheses or guidelines pooled it, 339 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Raj ChovatiyaDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Amy S PallerDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: apaller@northwestern.edu.
Northwestern University · US

Funding

AHRQ HHS K12 HS026385
6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous presentation and often immense patient burden. Safe, targeted treatment options are currently limited. This focused review of the published literature, including clinical trial results, case reports, and abstracts, as well as presentations from scientific meetings and data from industry press releases, describes the use of topical and systemic Janus kinase (JAK) inhibitors in the treatment of AD. New topical JAK inhibitors include ruxolitinib (JAK1/2) and delgocitinib (pan-JAK). Ruxolitinib cream met all primary and secondary endpoints in phase 3 clinical trials for mild-to-moderate AD with minimal treatment-emergent adverse events. Delgocitinib ointment was recently approved in Japan for pediatric and adult AD. Oral JAK inhibitors include baricitinib (JAK1/2), abrocitinib (JAK1-selective), and upadacitinib (JAK1-selective). All 3 met primary and secondary endpoints across numerous trials for moderate-to-severe AD. Treatment-emergent adverse events were mainly mild to moderate and included acne, nausea, headache, upper respiratory tract infection, and to a lesser degree, herpes infection and selected laboratory abnormalities. JAK inhibitors hold great promise as the next generation of targeted AD therapy. While their outstanding efficacy is balanced by a favorable safety profile in clinical trials, real-world data are needed to better understand long-term safety, durability, and treatment success.

Indexed as

Administration, OralAdministration, TopicalDermatitis, AtopicHumansJanus Kinase InhibitorsJanus Kinase InhibitorsAtopic dermatitiseczemaitchJAK inhibitortherapy

Identifiers

PMID34437922
PMCPMC10166130
OpenAlexW3194970552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.